[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622371":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":21,"responsibleParty":39,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":10,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Prospective Observational Cohort",null,"Utilizing baseline biospecimens for analysis of predictors of cardiotoxicity events and cancer outcomes after ICI initiation.",[13],{"name":14,"affiliation":5,"role":15},"Nicolas Palaskas, MD","PRINCIPAL_INVESTIGATOR",[17],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","832-750-1109","nlpalaskas@mdanderson.org",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"The University of Texas M. D. Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-95.36327,29.76328,{"lat":34,"lon":33},[37,38],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},{"name":14,"role":15,"phone":10,"phoneExt":10,"email":10},{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100622371","decoupling-immunotherapy-toxicity-and-cancer-response-100622371",false,"NCT07382752","Decoupling Immunotherapy Toxicity and Cancer Response","Metabolomic and Genetic Factors Decoupling Immune Checkpoint Inhibitor Tumor Efficacy and Cardiovascular Toxicity","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Plan to start immune checkpoint inhibitor for cancer therapy\n\nExclusion Criteria:\n\n1. No baseline blood collection prior to initiation\n2. At time of evaluation not determined to be a good candidate for evaluation of outcome events by the principal investigator","ALL","18 Years",{"count":51,"type":52},1200,"ESTIMATED","OBSERVATIONAL","This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension of previous work in ICI therapy.",[56,57],"Tumor","Cardiovascular","2026-01-26",{"date":60,"type":61},"2026-02-03","ACTUAL",{"date":63,"type":61},"2026-01-09",{"date":65,"type":52},"2030-06-30",{"name":5,"class":6},1]